Messina Monica, Piciocchi Alfonso, Siena Leonardo M, Soddu Stefano, Buccisano Francesco, Mecucci Cristina, Martinelli Giovanni, Curti Antonio, Cairoli Roberto, Fazi Paola, Vignetti Marco, Voso Maria Teresa, Venditti Adriano, Candoni Anna
Fondazione GIMEMA Rome Italy.
Department of Public Health and Infectious Diseases Sapienza University of Rome Rome Italy.
EJHaem. 2024 Nov 22;5(6):1274-1277. doi: 10.1002/jha2.1045. eCollection 2024 Dec.
Given the limited data on the real-life therapeutic use of feline McDonough sarcoma (FMS)-like tyrosine kinase 3 (FLT3) inhibitors in Italy, we surveyed investigators at 59 Italian hematology centers to gain insight into the proportion of acute myeloid leukemia (AML) patients receiving FLT3 inhibitors and we collected data on the efficacy and safety of these agents. The survey results showed that in the real-life setting the response rate of the 3/7 + midostaurin regimen in newly diagnosed FLT3-mutated AML and of gilteritinib in the relapsed/refractory AML were comparable to that reported in the registrative clinical trials. The 3/7 + midostaurin treatment resulted in a 63% of complete remission (CR) rates and gilteritinib in a 44% of CR rates. The discontinuation rate of gilteritinib for intolerance or toxicity was low (accounting for 4% of treated cases).
鉴于意大利关于猫 McDonough 肉瘤（FMS）样酪氨酸激酶 3（FLT3）抑制剂实际治疗应用的数据有限，我们对意大利 59 家血液学中心的研究人员进行了调查，以深入了解接受 FLT3 抑制剂治疗的急性髓系白血病（AML）患者的比例，并收集了这些药物的疗效和安全性数据。调查结果显示，在实际临床中，新诊断的 FLT3 突变型 AML 患者使用 3/7 + 米哚妥林方案以及复发/难治性 AML 患者使用吉瑞替尼的缓解率与注册临床试验中报告的缓解率相当。3/7 + 米哚妥林治疗的完全缓解（CR）率为 63%，吉瑞替尼治疗的 CR 率为 44%。吉瑞替尼因不耐受或毒性而停药的比例较低（占治疗病例的 4%）。
